The first patient was dosed in DOMMINO-1, a Phase 2 open-label, single-arm study enrolling 100 adult patients across clinical sites in the UK and U.S.. It could potentially offer an accelerated approval opportunity if it reaches a high enough response rate.

He describes the science behind Coya's combination therapies, and programs targeting ALS (currently in a phase 2 study), FTD, and Alzheimer's.

He discusses Insmed, IDEAYA, Bicycle, Compass Pathways, Revolution Medicines, Cytokinetics, and CG Oncology Chapters General sentiment - 1:25 Insmed - 3:16 IDEAYA - 7:07 Bicycle - 9:44 Compass Pathways - 13:04 Revolution, Cytokinetics, CG - 16:03

She describes how Q32's therapy, bempikibart, is almost like a natural bispecific because it blocks both IL-7 and TSLP. It could be the first biologic developed for this condition.

With eight facilities in the metro Boston area, he describes the contract vivarium model, and how it is designed to avoid the need to outsource your early stage science.

She highlights the goal of the accelerator, which meets monthly online, and also will have an in-person symposium in October. Plus, science that interests her, including "nodal" biologic pathways. Learn more about the Ladders to Cures Scientific Accelerator

She highlights a bill she has filed to help fill the gap left by reduced federal funding for research, and also the non-monetary initiatives, like quality of life, that the state can do to retain talent.

CEO Atul Deshpande describes how every minute counts after a heart attack yet patients typically do not receive and medicine until they reach the hospital. He explains what IMMEDIATE's solution is, which is phase 3 ready and has a SPA from FDA.

He describes data presented at the 2026 Muscular Dystrophy Association Annual Meeting, which showed biopsy and safety data for 20 patients who have been followed for 90 days and 3 who are out to a year. Plus, explaining the three FDA meetings that are key for the company.

Michal Preminger will lead BioMed X Venture labs as CEO, and it will partner with pharma, foundations, and VCs to build mission driven companies.

He discusses the the data and how he compares it to Dupixent and other medicines on the market, how translatable the data might be to a phase 3 that will be up and running later this year, and what other data the company will have in the near future.

Simeon George discusses his early days at SR One while it was part of GSK, and the transition to making the firm independent in 2020. Plus, the importance of peer-to-peer collaboration, and his how he thinks about investing in different indications and modalities. Chapters Intro and early life - 0:43 Hopkins and early work - 6:41 Joining SR One - 14:45 2007 to 2020 / GSK - 23:51 Going independent - 27:49 2020 to present - 33:45 Peer-to-peer collaboration - 41:13 Therapeutics

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Zag Bio CEO Jason Cole and Altido Therapeutics CEO Chip Clark about running early stage companies and what advice they have for new CEOs. They offer advice about what it will take to keep our ecosystem globally competitive. Chapters Zag Bio - 1:03 Altido Therapeutics - 2:12 Massachusetts - 3:00 Culture- 5:11 Different skill sets - 7:11 Getting through challenge - 9:12 Early stage companies - 15:27 F

From Syncona's Capital Markets Day, he describes Slingshot and how he believes it differs from other early stage VC investors. Once an asset is ready for the clinic, Slingshot will either partner it or build its own company.